about
Subjective discomfort in children receiving 3 T MRI and experienced adults' perspective on children's tolerability of 7 T: a cross-sectional questionnaire surveyImaging gray matter with concomitant null point imaging from the phase sensitive inversion recovery sequenceHeadache: two views on the right approach in general practice.Amiloride Clinical Trial In Optic Neuritis (ACTION) protocol: a randomised, double blind, placebo controlled trial.Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS): study protocol for a randomised controlled trialStatus of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes.Role of oral teriflunomide in the management of multiple sclerosis.Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution.Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.Primary care direct access MRI for the investigation of chronic headache.The current state-of-the-art of spinal cord imaging: methods.Postpartum headache: diagnostic considerations.A comparison of 3T and 7T in the detection of small parenchymal veins within MS lesions.Improved detection of focal cortical lesions using 7T magnetisation transfer imaging in patients with multiple sclerosis.Central veins in brain lesions visualized with high-field magnetic resonance imaging: a pathologically specific diagnostic biomarker for inflammatory demyelination in the brain.Cortical lesion load correlates with diffuse injury of multiple sclerosis normal appearing white matter.Spinal cord gray matter demyelination in multiple sclerosis-a novel pattern of residual plaque morphology.Spinal cord neuronal pathology in multiple sclerosis.Optimisation of T₂*-weighted MRI for the detection of small veins in multiple sclerosis at 3 T and 7 T.New imaging language skills required in MS.Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis.Rationing and deprivation: disease-modifying therapies for multiple sclerosis in the United KingdomSpinal Cord Atrophy in Multiple Sclerosis Caused by White Matter Volume LossAnatomy of the Retina and the Optic NerveQuantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis3 Tesla and 7 Tesla MRI of multiple sclerosis cortical lesionsThe only way to manage neurodegeneration in MS is to prevent it with effective anti-inflammatory therapy: yesCatastrophic brain relapse in seronegative NMO after a single dose of natalizumabDetection of central vein should be part of MS diagnostic criteria - YesClinical observation during alemtuzumab administrationValue of 3T Susceptibility-Weighted Imaging in the Diagnosis of Multiple Sclerosis
P50
Q30428038-5D19D738-1237-4714-B649-9911912135C5Q30488582-048E73A0-3429-4BAD-9462-8B812CE553E5Q34078046-852937D5-DECC-4402-ABE4-EEE315F58C83Q35836853-908103F9-744A-44B2-9330-FE966F496832Q36163721-6102EDF7-4047-47D3-AFDA-59A0329192B1Q36753462-86D01B4C-1FBA-46AA-8DFF-B887729B62E4Q36803649-55158E59-7E41-436F-B85F-B2551E872EA0Q36850891-3512D300-BB7D-4E77-ACC4-C2CC0B79011EQ37322100-E948418F-4433-42F6-B51B-F0EA4FB58848Q37956746-1A22AA79-AD08-4F9D-8E81-636F751A3BB1Q38107745-0D1A74D2-338A-4429-A585-C443A20986C4Q38132371-7C03D906-C680-45FA-BC1B-753BA44AECF6Q39958173-F11566DB-D0DA-4F2A-9E3F-D002212B4AB6Q41067314-38E2FC3A-C71A-4F47-86D1-A0DDC08965ADQ44620771-45EC51C5-CC82-4131-8B55-5C6094449BB1Q46154612-3B35DF45-CB65-4F4B-AD24-A5D7B8EF7EF7Q48446542-3C471E45-5AF1-460F-9D09-DFE5AFDA47CFQ48787320-3AFD4372-F414-4C08-A5FA-DF83A26BAF93Q51483026-35BA1F0E-1DB7-4803-81BA-172A9AF3110DQ52150264-643218B4-9702-4105-A6AE-C315BEC4AF40Q52927685-7FF85CBD-A0F6-4EAB-965E-87F7323FB88BQ57573402-DB1F5DCC-020B-476A-ACAA-A47C967A7E93Q57573407-4B670760-F639-40E1-A1BA-6A372DFEEF7EQ63185102-96751E69-49CB-43CB-B639-E40C6F011175Q73546566-B207C283-2EC6-4BA9-87B9-19CCFB7EFCD0Q85113517-F4AA2F43-E0DA-4C68-973E-AC82B399057EQ85648605-6175159A-A49F-4A2F-BCEC-D123F2EC6B49Q87372644-7BE611B6-4808-4A8E-926F-331C3BE416C5Q89991265-9666D2B3-23DC-40C9-8BC2-FF7A02E1A1DEQ90334628-9052D3A3-BA9F-400D-B89E-79DB9721EEFAQ95316340-567237D4-5139-4F22-8B52-72848AA17948
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nikos Evangelou
@ast
Nikos Evangelou
@en
Nikos Evangelou
@es
Nikos Evangelou
@nl
type
label
Nikos Evangelou
@ast
Nikos Evangelou
@en
Nikos Evangelou
@es
Nikos Evangelou
@nl
prefLabel
Nikos Evangelou
@ast
Nikos Evangelou
@en
Nikos Evangelou
@es
Nikos Evangelou
@nl
P106
P31
P496
0000-0003-2871-0672